Clinical Trial Update: Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause [Phase 3]

View source ↗

Summary

A Phase 3 trial of intravaginal prasterone (DHEA) for vulvovaginal atrophy due to menopause has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vaginal Atrophy

Drugs mentioned

• Intrarosa (prasterone) (prasterone)

Snippet

Sponsor: EndoCeutics Inc. | Conditions: Vaginal Atrophy | Phase 3 | Status: COMPLETED | Results posted: 2017-06-01